KNSA vs TAP · P/E 53, rev $677.6M vs rev $13.04B
Kiniksa Pharmaceuticals Ltd (KNSA) versus TAP (TAP) — a side-by-side from cached financials, not a winner call.
Kiniksa Pharmaceuticals Ltd (KNSA) is a drug manufacturers - specialty & generic company listed on US.
TAP (TAP) common stock.
Latest reported KNSA revenue for 2025-12-31 was $677.6M. Net income was $59.0M. Revenue was up 60.1% from 2024-12-31 to 2025-12-31. KNSA currently screens at market cap $3.73B and trailing P/E 53.2.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
KNSA currently screens at market cap $3.73B and trailing P/E 53.2. TAP currently screens at market cap $0.
Not investment advice. Open the KNSA and TAP stock pages for the full models.
Not investment advice.